文献速递白血病

儿童B细胞前体急性淋巴细胞白血病晚期骨髓复发长期随访结果

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.
PubMed 文献 · Lancet Haematol · 2019-02-27

ALLR3开放标签随机试验长期随访分析儿童B细胞前体急性淋巴细胞白血病晚期骨髓复发患者。中位随访84个月,全部随机分组患者无进展生存率60%。诱导结束时微小残留病高者5年无进展生存率56%,低者72%(p=0.0078)。低微小残留病患者化疗未行移植结局良好,高微小残留病患者受益于干细胞移植。

要点

  • 全部随机分组患者中位随访84个月无进展生存率为60%(95%CI 54-70)。
  • 诱导结束高微小残留病者5年无进展生存率56%,低者72%,差异有统计学意义(p=0.0078)。
  • 低微小残留病患者化疗未行移植结局良好;高微小残留病患者受益于干细胞移植。

核心结论

  • 晚期骨髓复发且诱导结束时微小残留病低的B细胞前体急性淋巴细胞白血病患者化疗未行干细胞移植结局良好。
  • 微小残留病高者受益于干细胞移植,靶向治疗可能进一步改善这些患者的结局。

研究设计与样本

  • ALLR3为开放标签随机临床试验,招募1-18岁晚期骨髓复发B细胞前体急性淋巴细胞白血病儿童,来自澳大利亚、爱尔兰、荷兰、新西兰和英国的中心。
  • 患者于2003年1月31日至2007年12月31日随机分组,试验于2013年10月31日停止招募。
  • 随机分组患者接受伊达比星或米托蒽醌诱导治疗;2007年12月31日随机化停止后所有患者接受米托蒽醌。
  • 三块治疗后,诱导结束时微小残留病高(≥10^-4细胞)者分配至异基因干细胞移植,微小残留病低(<10^-4细胞)者分配至化疗。
  • 微小残留病水平通过免疫球蛋白和T细胞受体基因重排的实时定量PCR分析测量。

主要发现

  • 2003年2月2日至2013年10月28日共治疗228例晚期骨髓复发B细胞前体急性淋巴细胞白血病患者。
  • 中位随访84个月(IQR 48-109),全部随机分组患者无进展生存率为60%(95%CI 54-70)。
  • 220例达到第二次完全缓解,192例(87%)微小残留病可评估。
  • 分配至干细胞移植的110例高微小残留病患者中,移植前报告4例复发和3例死亡,11例未移植。
  • 92例接受移植者中58例(63%)维持第二次完全缓解,13例(14%)死于并发症,21例(23%)移植后复发。

关键数值与推荐

  • 分配至化疗的低微小残留病患者中报告1例早期治疗相关死亡,11例接受了移植。
  • 继续化疗的70例患者中49例(70%)维持第二次完全缓解,2例(3%)死于并发症,19例(27%)复发。
  • 高微小残留病患者5年无进展生存率为56%(95%CI 46-65),低微小残留病患者为72%(60-81)(p=0.0078)。
  • 长期随访中未分析治疗相关严重不良事件。

临床怎么用

  • 晚期骨髓复发且诱导结束时微小残留病低的B细胞前体急性淋巴细胞白血病患者化疗未行干细胞移植结局良好。
  • 微小残留病高者受益于干细胞移植。
  • 作者认为靶向治疗可能进一步改善高微小残留病患者的结局。

局限性

  • 长期随访中未分析治疗相关严重不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ALLR3 trial investigated outcomes of children with B-cell precursor acute lymphoblastic leukaemia who had late bone marrow relapses. We analysed long-term follow-up outcomes of these patients. METHODS: ALLR3 was an open-label randomised clinical trial that recruited children aged 1-18 years with B-cell precursor acute lymphoblastic leukaemia who had late bone marrow relapses. Eligible patients were recruited from centres in Australia, Ireland, the Netherlands, New Zealand, and the UK. Patients were randomly assigned from Jan 31, 2003, to Dec 31, 2007, and the trial closed to recruitment on Oct 31, 2013. Randomly assigned patients were allocated to receive either idarubicin or mitoxantrone in induction by stratified concealed randomisation; after randomisation stopped in Dec 31, 2007, all patients were allocated to receive mitoxantrone. After three blocks of therapy, patients with high minimal residual disease (≥10-4 cells) at the end of induction were allocated to undergo allogeneic stem-cell transplantation and those with low minimal residual disease (<10-4 cells) at the end of induction were allocated to receive chemotherapy. Minimal residual disease level was measured by real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements. The primary endpoint of the original ALLR3 clinical trial was progression-free survival of randomly assigned patients. The primary endpoint of this long-term follow-up analysis was progression-free survival of patients with late bone marrow relapses stratified by minimal residual disease level. Outcomes were correlated with age, site, time to recurrence, and genetic subtypes, and analysed by both intention to treat and actual treatment received. This trial is registered on the ISRCTN registry, number ISRCTN45724312, and on ClinicalTrials.gov, number NCT00967057. FINDINGS: Between Feb 2, 2003, and Oct 28, 2013, 228 patients with B-cell precursor acute lymphoblastic leukaemia and late bone marrow relapses were treated. After a median follow-up of 84 months (IQR 48-109), progression-free survival of all randomly assigned patients was 60% (95% CI 54-70). 220 patients achieved second complete remission, and minimal residual disease was evaluable in 192 (87%). 110 patients with late bone marrow relapses and high minimal residual disease at the end of induction were allocated to undergo stem-cell transplantation, and 82 patients with low minimal residual disease at the end of induction were allocated to receive chemotherapy. In the patients allocated to undergo stem-cell transplantation, four relapses and three deaths were reported before the procedure, and 11 patients were not transplanted. Of the 92 patients transplanted, 58 (63%) remained in second complete remission, 13 (14%) died of complications, and 21 (23%) relapsed after stem-cell transplantation. In patients allocated to receive chemotherapy, one early treatment-related death was reported and 11 patients were transplanted. Of the 70 patients who continued on chemotherapy, 49 (70%) remained in second complete remission, two (3%) died of complications, and 19 (27%) relapsed. Progression-free survival at 5 years was 56% (95% CI 46-65) in those with high minimal residual disease and 72% (60-81) in patients with low minimal residual disease (p=0·0078). Treatment-related serious adverse events were not analysed in the long-term follow-up. INTERPRETATION: Patients with B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses and low minimal residual disease at end of induction had favourable outcomes with chemotherapy without undergoing stem-cell transplantation. Patients with high minimal residual disease benefited from stem-cell transplantation, and targeted therapies might offer further improvements in outcomes for these patients. FUNDING: Bloodwise (Formerly Leukaemia and Lymphoma Research) UK, Cancer Research UK, Sporting Chance Cancer Foundation, National Health and Medical Research Council Australia, KindreneKankervrij Netherlands, European Union Seventh Framework Programme, India Alliance Wellcome DBT Margdarshi Fellowship.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Parker C, Krishnan S, Hamadeh L, et al. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. Lancet Haematol. 2019. PMID: 30826273. doi:10.1016/S2352-3026(19)30003-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。